Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Year: 2024
Type: article
Abstract: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS), termed primary CNS lymphoma (PCNSL), is an aggressive neoplasm presenting with disease limited to the CNS. PCNSL was recognised as a distinct entity by the 2017 World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues.1 In the 2022 edition of the WHO classification,2 this neoplasm is classified in the ‘Large B-cell lymphomas of immune-privileged sites’ group, whereas it is considered a specific entity in the International Consensus Classification of Mature Lymphoid Neoplasms.
Source: Annals of Oncology
Institutions: Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Klinikum Stuttgart, Erasmus MC, Erasmus MC Cancer Institute, University of Nottingham, Nottingham Biomedical Research Centre, University College Hospital, Sorbonne Université, Pitié-Salpêtrière Hospital, Institut du Cerveau, Inserm, Université Paris Sciences et Lettres, Institut Curie, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, University of Freiburg, University Medical Center Freiburg, University of Copenhagen, Rigshospitalet, University of Bern, University Hospital of Bern, Ente Ospedaliero Cantonale, Institute of Oncology Research, Istituto Oncologico della Svizzera Italiana, Università della Svizzera italiana, Universität Ulm, University Hospital Ulm, Lund University, Skåne University Hospital, LMU Klinikum, Ludwig-Maximilians-Universität München
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,600
OpenAlex ID: W4399318895